aacr.org
Aug 24, 2025, 13:40
Jean-Charles Soria: Circulating Tumor Cells
Jean-Charles Soria, SVP and Oncology Therapeutic Area Head at Amgen, shared on LinkedIn:
“Circulating Tumor Cells: Beyond ctDNA in Precision Oncology
CTCs ≠ ctDNA: Beyond mutations, CTCs reveal real-time protein and RNA expression – useful for target discovery and resistance monitoring.
Liquid biopsy advantage: Noninvasive CTC analysis enables dynamic tracking of tumor evolution, therapy response and MRD.
Prognostic power: High CTC counts in early disease predict relapse; in metastatic disease, counts stratify prognosis and guide treatment intensity.
Therapeutic targets: HER2, ER, AR, PSMA, PD-L1, EGFR, ALK—CTCs expose actionable biomarkers and resistance mechanisms in real time.”
More posts featuring Jean-Charles Soria.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 24, 2025, 13:40
Aug 24, 2025, 13:37
Aug 24, 2025, 13:30
Aug 24, 2025, 12:40
Aug 24, 2025, 12:35
Aug 24, 2025, 12:33
Aug 24, 2025, 12:08
Aug 24, 2025, 11:58
Aug 24, 2025, 11:46